Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-108 Single Agent or Combo with Pembrolizumab in Advanced Solid Tumors
NCT05255484Phase 2Terminated
- Sponsor
- LaNova Medicines
- Start
- May 2022
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial of LM-108 in solid tumor (advanced stage) (4 arms), sponsored by LaNova Medicines. Primary endpoints: Adverse Events at 126 weeks, Dose Limiting Toxicity at 21 days and 2 more. Started May 2022; status: terminated.
02
Drugs
LM-108
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05255484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255484.